000			05216nam a22003855i 4500
710	2		_aSpringerLink (Online service) _0Local _9106996
999			_c86688 _d86688 _x1
001			86688
003			ES-MaUEC
005			20230207040610.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			160930s2016 ii | s |||| 0|eng d
020			_a9788132228370
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC267 _b2016 EB
245	0	0	_aBiomarker Discovery in the Developing World: Dissecting the Pipeline for Meeting the Challenges _cedited by Sanjeeva Srivastava
264		1	_aNew Delhi _bSpringer India _c2016
300			_a1 recurso en línea (XI, 118 páginas) _b28 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aChapter 1: Exigencies of biomarker research in developing world: A focus on the dearth of biobanking resources -- Chapter 2: Geographic pervasiveness of cancer: Prospects of novel biomarker and therapeutic research in developing countries using OMICs approaches -- Chapter 3: Omics data processing and analysis -- Chapter 4: Basics of mass spectrometry and its applications in biomarker discovery -- Chapter 5: Angel Philanthropy and Crowdfunding to Accelerate Cancer Research in Developing World -- Chapter 6: Delivering on the Promise of Bioeconomy in Developing World: Link it with Social Innovation and Education -- Chapter 7: Role of proteomics in characterization of biosimilar products -- Chapter 8: Regulatory norms and intellectual property rights for biomarker research.
520			_aThis book is oriented towards post-graduates and researchers with interest in proteomics and its applications in clinical biomarker discovery pipeline. Biomarker discovery has long been the research focus of many life scientists globally. However, the pipeline starting from discovery to validation to regulation as a diagnostic or therapeutic molecule follows a complex trajectory. This book aims to provide an in-depth synopsis on each of these developmental phases attendant to biomarker zlife cycley with emphasis on the emerging and significant role of proteomics. The book begins with a perspective on the role of biorepositories and need for biobanking practices in the developing world. The next chapter focuses on disease heterogeneity in context to geographical bias towards susceptibility to the disease and the role of multi-omics techniques to devise disruptive innovations towards biomarker discovery. Chapter 3 focuses on various omics-based platforms that are currently being used for biomarker discovery, their principles and workflow. Mass spectrometry is emerging as a powerful technology for discovery based studies and targeted validation. Chapter 4 aims at providing a glimpse of the basic workflow and considerations in mass spectrometry based studies. Rapid and aptly targeted research funding has often been deemed as one of the decisive factors enabling excellent science and path breaking innovations. With theneed for sophistication required in multi-omics research, Chapter 5 focuses on innovative funding strategies such as crowdfunding and Angel philanthropy. Chapter 6 provides the latest advances in education innovation, the premise and reality of bioeconomy especially in a specific context of the developing world, not to mention the new concept of zsocial innovationy to link biomarkers with socially responsible and sustainable applications. Chapter 7, in ways similar to biomarkers, discusses the biosimilars as a field that has received much focus and prominence recently due to their immense potential in clinical and pharmaceutical innovation literatures. The broader goal post-biomarker discovery is to translate their use in clinics. However, the road from bench-to-bed side is arduous and complex that is subject to oversight from various national and international regulatory bodies. Chapter 8 underscores these regulatory science considerations and provides a concise overview on intellectual property rights in biomarker discovery. Thus, this book contributed by eminent biomarker scientists, clinicians, translational researchers and social scientists holistically covers the various facets of the biomarker discovery journey from zcell to societyy in developing world. The lessons learned and highlighted here are of interest to the life sciences community in a global and interdependent world.
988	0	0	_aEBOOK, EBSPRINGER
650		7	_aCáncer _xInvestigación _0comprobar BNE19901364217 _2embne _9182523
650		7	_aMarcadores biológicos _2embne _9162047
700	1		_aSrivastava, Sanjeeva. _eeditor literario _9100587 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-81-322-2837-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9788132228370
907			_a.b12959662 _b10-10-17 _c21-11-16
942			_2lcc _cLE
945			_aEBOOK EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i1161612x _z30-06-17
998			_b05/2020 _dz _eu _feng _gii _h0